Forty three Eighteen Advisors LLC Invests $635,000 in CVS Health Corporation $CVS

Forty three Eighteen Advisors LLC acquired a new position in shares of CVS Health Corporation (NYSE:CVS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 8,000 shares of the pharmacy operator’s stock, valued at approximately $635,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new position in CVS Health in the fourth quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd raised its position in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new stake in CVS Health in the fourth quarter valued at approximately $28,000. Finally, Ares Financial Consulting LLC bought a new stake in CVS Health in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS opened at $98.26 on Friday. The firm has a market capitalization of $125.38 billion, a PE ratio of 43.29, a PEG ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $102.77. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm’s fifty day simple moving average is $89.31 and its 200 day simple moving average is $81.48.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last three months. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $113.00 price target on shares of CVS Health in a report on Monday, June 1st. JPMorgan Chase & Co. increased their target price on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. UBS Group raised their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a report on Monday, June 8th. Wells Fargo & Company boosted their price target on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Royal Bank Of Canada upped their price target on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.